These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37329429)

  • 1. Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study.
    Gutierrez-Sainz L; Martinez-Fdez S; Pedregosa-Barbas J; Peña J; Alameda M; Viñal D; Villamayor J; Martinez-Recio S; Perez-Wert P; Pertejo-Fernandez A; Gallego A; Martinez-Marin V; Zamora P; Espinosa E; Mendiola M; Feliu J; Redondo A
    Clin Transl Oncol; 2023 Dec; 25(12):3519-3526. PubMed ID: 37329429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
    Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
    Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
    Italiano A; Toulmonde M; Bui-Nguyen B
    Bull Cancer; 2010 Jun; 97(6):679-86. PubMed ID: 20483708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
    Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
    BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
    Kim JH; Park HS; Heo SJ; Kim SK; Han JW; Shin KH; Kim SH; Hur H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim HS
    Oncology; 2019; 96(2):59-69. PubMed ID: 30336470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Grignani G; Martín-Broto J; Schuler M; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
    Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
    Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
    Sharma S; Takyar S; Manson SC; Powell S; Penel N
    BMC Cancer; 2013 Aug; 13():385. PubMed ID: 23937858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
    Van Tine BA; Trent JC
    Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
    Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
    Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
    García-Del-Muro X; López-Pousa A; Maurel J; Martín J; Martínez-Trufero J; Casado A; Gómez-España A; Fra J; Cruz J; Poveda A; Meana A; Pericay C; Cubedo R; Rubió J; De Juan A; Laínez N; Carrasco JA; de Andrés R; Buesa JM;
    J Clin Oncol; 2011 Jun; 29(18):2528-33. PubMed ID: 21606430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.
    Hara H; Kawamoto T; Fukase N; Kawakami Y; Takemori T; Fujiwara S; Kitayama K; Nishida K; Kuroda R; Akisue T
    BMC Cancer; 2019 Jul; 19(1):725. PubMed ID: 31337342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
    Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
    Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
    Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M;
    Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
    Ferraresi V; Ciccarese M; Cercato MC; Nuzzo C; Zeuli M; Di Filippo F; Giannarelli D; Cognetti F
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):149-55. PubMed ID: 18351342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
    van Oosterom AT; Mouridsen HT; Nielsen OS; Dombernowsky P; Krzemieniecki K; Judson I; Svancarova L; Spooner D; Hermans C; Van Glabbeke M; Verweij J;
    Eur J Cancer; 2002 Dec; 38(18):2397-406. PubMed ID: 12460784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
    Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
    PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.